Navigation Links
Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL)
Date:1/26/2010

COLUMBUS, Ohio, Jan. 26 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the New Drug Application (NDA) approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL bottles as of January 25th, 2010 by the Food and Drug Administration. This product is indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate.

Roxane Laboratories', Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) is the only FDA approved Morphine Sulfate Oral Solution CII available at this concentration. Roxane Laboratories, Inc. has sufficient supply to meet the entire market demand and no shortage is anticipated. Roxane Laboratories, Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL), will be transitioning to new packaging, labeling, and NDC numbers in the near future. In the mean time, please continue to use the following Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) NDC numbers:

NDC 0054-0352-44 Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL Bottle

NDC 0054-0352-50 Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 120mL Bottle

Roxane Laboratories, Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL is available for immediate shipment to wholesalers and pharmacies nationwide.

Full prescribing information for Morphine Sulfate Oral Solution CII is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories, Inc. is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories, Inc. markets more than 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17.0 billion (euro 11.6 billion) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

SOURCE Roxane Laboratories, Inc.

RELATED LINKS
http://www.Roxane.com

'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
7. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
8. Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
9. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
10. Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, handbooks, ... and more. , To access more than 9,000 documents, webinars and videos ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's important ... This is the idea behind Safe Toys and Gifts Month, which sets aside December ... gifts for children. For companies that produce goods that fall into this category, it's ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... been featured in SuperbCrew magazine, a leading online tech news platform connecting technology ... now featured on SuperbCrew.com, explores the state of enterprise mobility security today, and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Special purpose needles are used in target specific ... cells from organs or lumps and are available in the ... market for special purpose needles is showing a steady growth ... the global special purpose needles market is projected to expand ... and is expected to be valued at US$ 17,261.5 million ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Institute for the Commercialization of Public Research ... finalized a funding agreement SegAna, LLC, an ... at University of Central Florida. The Florida Institute ... and bridges early funding gaps for companies spinning ...
Breaking Medicine Technology: